Ardelyx (NASDAQ: ARDX) shares are trading lower after the company received an FDA letter regarding its NDA for tenapanor indicating deficiencies that preclude discussion of labeling and post-marketing requirements/comments at this time.  Ardelyx Inc. is a biopharmaceutical company that develops and sells medicines fo
Full Story >>
Vote
+28